<! –

->

July 31, 2018 – By Hazel Jackson

Investor sentiment decreased to 1.57 in Q1 2018. It is down 0.35 from 1.92 in 2017Q4. It is negative, since 11 investors sold shares of Immune Design Corp. while 12 reduced their holdings. 10 funds opened positions while 26 increased issues. 21.61 million shares, or 6.41% less than 23.09 million shares in the fourth quarter of 2017.
Guggenheim Capital Llc holds 0% or 11,306 shares of its portfolio. 34,256 are held by Deutsche State Bank Ag. Focused Wealth Management Incorporated invested in 12,395 shares, representing 0.01% of the capital. California-based Wells Fargo & Co Mn invested 0% in Immune Design Corp. (NASDAQ: IMDZ). Illinois-based Balyasny Asset Management Ltd. invested 0% in Immune Design Corp. (NASDAQ: IMDZ). Mbadachusetts-based Panagora Asset Mgmt Inc. invested 0.01% in Immune Design Corp. (NASDAQ: IMDZ). Bath Cap Equity Pub Mgmt Ltd Liability Corp. has 1.68 million shares. Thompson Davis reported 250 shares. Jpmorgan Chase And Communication holds 842,927 shares. Goldman Sachs Inc Inc. invested 0% in Immune Design Corp. (NASDAQ: IMDZ). Fmr Limited Liability Company has accumulated 1.18 million shares. Weiss Multi has accumulated 80,000 shares. Personal Cap Advisors Corporation holds 0% or 24,000 shares. Drw Securities Limited holds 37,000 shares. Barclays Public Ltd Liability Corp. stated that it has 6,685 shares or 0% of all its holdings.

Analysts are waiting at Immune Design Corp. (NASDAQ: IMDZ) from $ -0.30 EPS on August 1st. They expect a change of EPS 0.24 or 44.44% of earnings per share of -0.54 $ in the previous quarter. After previously recording earnings per share of -0.28, badysts at Immune Design Corp. reported EPS growth of 7.14%. The stock rose 5.56% or $ 0.2 during the last trading session, reaching $ 3.8. Approximately 292,969 shares were traded, 23.76% above average. Immune Design Corp. (NASDAQ: IMDZ) has fallen 47.53% since August 1, 2017 and is on the decline. It underperformed the S & P 500 by 60.10%.

Immune Design Corp., a clinical stage immunotherapy company, engaged in the research and development of in vivo therapeutics for cancer. The company has a market capitalization of $ 182.88 million. He mainly develops oncology product candidates based on his ZVex and GLAAS product discovery platforms. He currently has negative gains. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 which is in phase 1 trial for the treatment of patients with recurrent or metastatic melanoma, sarcoma, ovarian cancer or cancer non-small cell lungs that express NY-ESO-1; and G100, a candidate intratumoral immune activation product for the treatment of patients with a cell carcinoma of Merkel and a non-Hodgkin's lymphoma.

Another important and recent news from Immune Design Corp. (NASDAQ: IMDZ) was published by Nasdaq.com. article titled: "Immune Design to Announce Second Quarter 2018 Financial Results and Provide a Business Update" on July 25, 2018.

By Hazel Jackson